@article {Kalaycio913, author = {Matt E. Kalaycio}, title = {Chronic myelogenous leukemia: The news you have and haven{\textquoteright}t heard}, volume = {68}, number = {11}, pages = {913--926}, year = {2001}, publisher = {Cleveland Clinic Journal of Medicine}, abstract = {Chronic myelogenous leukemia (CML) can usually be cured by bone marrow transplantation from matched donors. Donor T-cell activity from the graft is critical to maintaining remission. Myeloablation may not be necessary for cure. Non-myeloablative but immunosuppressive preparative regimens allow donor engraftment with less toxicity. Early combination therapy with interferon-alfa and cytarabine was the preferred option for patients who could not undergo bone marrow transplantation. Now, the advent of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, promises to change existing treatment paradigms}, issn = {0891-1150}, URL = {https://www.ccjm.org/content/68/11/913}, eprint = {https://www.ccjm.org/content/68/11/913.full.pdf}, journal = {Cleveland Clinic Journal of Medicine} }